My watch list


Medical Imaging in Clinical Research

in San Francisco from 12-Feb-2018 - 13-Feb-2018

There are significant benefits to using imaging during clinical trials. Imaging in early phases can be used as a biomarker to validate a hypothesis or to make Go/No Go Decisions to further drug development. During late phases, imaging data can contribute to the potential of expedited Health Authority approval process. However, when implementing imaging technology for the first time challenges can arise. The main challenge facing clinical operation teams during clinical research is the harmonization and standardization of imaging processes and data collection.

Study teams worry about standardization while working with many different sites. They need to ensure that the study imaging protocol is followed the same way at all various sites in the world. The scanning machines need to be regularly calibrated and maintained at every site, data collection needs to be uniform, data transferred to the CRO needs to follow identical processes, and the imaging Contract Research Organization (CRO) analyzes the data as per the study protocol. The analyzed data needs to be brought in-house in a standardized way to facilitate the statistician to demonstrate statistical significance of the data: which can ultimately prove the hypothesis or support the teams to further the development of their drug.

Certain technologies lend themselves nicely to clinical trial imaging. Structural MRI, PET and CT are readily available and widely used technologies in clinical trials – offering a lot of opportunity for late stage analysis. CEST MRI and task-fMRI are more complex, not as many vendors have the capabilities to use these technologies, making them not suitable for multifaceted studies.

Many large pharmaceutical companies have all the right personnel or know the right contacts to determine what technology they need to use and where for their clinical trials. The biggest opportunity with Medical Imaging in Clinical Research is pairing smaller pharmaceutical companies with the appropriate specialty CROs. The major CROs are set up and equipped to handle most imaging needs for clinical trials. However, smaller CROs are more specialized and narrowly focused – sometimes with more advanced capabilities.

Type of Event: Conferences
Event Date: 12-Feb-2018 to 13-Feb-2018
Event Location: Argonaut Hotel
San Francisco
Language: English
Event Organiser: EXL Events
  • imaging
  • clinical research

Topics A-Z

All topics

q&more – the networking platform for quality excellence in lab and process

The q&more concept is to increase the visibility of recent research and innovative solutions, and support the exchange of knowledge. In the broad spectrum of subjects covered, the focus is on achieving maximum quality in highly innovative sectors. As a modern knowledge platform, q&more offers market participants one-of-a-kind networking opportunities. Cutting-edge research is presented by authors of international repute. Attractively presented in a high-quality context, and published in German and English, the original articles introduce new concepts and highlight unconventional solution strategies.

> more about q&more

q&more is supported by:

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE